Drugs / 1,25 (OH)2 D3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03469271 | May 2018 → May 2020 | cancer | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1,25 (OH)2 D3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03469271 ↗ |
| Route | Oral | “1,25 (OH)2 D3 orally for eight weeks” NCT03469271 ↗ |